Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
ATH434's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for ATH434. Showing past 6 months and next 12 months · 6 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| ATH434 | Alterity Therapeutics | Small Molecule Other | Phase 2 | 0 | ||||
| Trial of Parkinson's And Zoledronic Acid | California Pacific Medical Center Research Institute | — | Phase 4 |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | Theravance Biopharma | — | Phase 3 | — | — | — | — | — |
| The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | Lupin Ltd. | — | Phase 3 | — | — | — | — | — |
| A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies | First Affiliated Hospital of Zhejiang University | — | Phase 3 | — | — | — | — | — |
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) | H. Lundbeck A/S | — | Phase 3 | — | — | — | — | — |
| MSA-01 in Multiple System Atrophy | Tokyo University | — | Phase 3 | — | — | — | — | — |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) | Biogen | — | Phase 3 | — | — | — | — | — |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) | ProQR Therapeutics | — | PHASE2/PHASE3 | — | — | — | — | — |
| Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy | Wuhan Neurophth Biotechnology Limited Company | — | PHASE2/PHASE3 | — | — | — | — | — |
| [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD | prof. dr. Koen Van Laere | — | PHASE2/PHASE3 | — | — | — | — | — |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy | Second Affiliated Hospital, School of Medicine, Zhejiang University | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Hoffmann-La Roche | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Study of Lu AF82422 in Participants With Multiple System Atrophy | H. Lundbeck A/S | — | Phase 2 | — | — | — | — | — |
| AMX0035 in Adult Patients With Wolfram Syndrome | Amylyx Pharmaceuticals Inc. | — | Phase 2 | — | — | — | — | — |
| Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome | University of Birmingham | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy | Ono Pharmaceutical Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) | Benedetto Falsini | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy | Dasher Neuroscience Inc. | — | Phase 2 | — | — | — | — | — |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | PepGen Inc | — | Phase 2 | — | — | — | — | — |
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy | BioArctic AB | — | Phase 2 | — | — | — | — | — |
| Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | Mayo Clinic | — | Phase 2 | — | — | — | — | — |
| A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | Actimed Therapeutics Ltd | — | Phase 2 | — | — | — | — | — |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | Tiziana Life Sciences LTD | — | Phase 2 | — | — | — | — | — |
| A Study of PLH-2301 in Subjects With Sarcopenia | Pluto Inc. | — | Phase 2 | — | — | — | — | — |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | Teva Branded Pharmaceutical Products R&D LLC | — | Phase 2 | — | — | — | — | — |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism | Haukeland University Hospital | — | Phase 2 | — | — | — | — | — |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy | Teva Branded Pharmaceutical Products R&D LLC | — | Phase 2 | — | — | — | — | — |
| Autologous Stem Cell Therapy in Patients With Multiple System Atrophy | Biocells Medical | — | Phase 2 | — | — | — | — | — |
| Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. | Eyestem Research Pvt. Ltd. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients | GeneCradle Inc | — | PHASE1/PHASE2 | — | — | — | — | — |
| Automated Abdominal Binder for Orthostatic Hypotension | Vanderbilt University Medical Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | BioMarin Pharmaceutical | — | PHASE1/PHASE2 | — | — | — | — | — |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | Julien Bally | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients | GeneCradle Inc | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | GeneCradle Inc | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Vertex Pharmaceuticals Incorporated | — | PHASE1/PHASE2 | — | — | — | — | — |
| Mesenchymal Stem Cell Therapy in Multiple System Atrophy | Mayo Clinic | — | PHASE1/PHASE2 | — | — | — | — | — |
| NS-050/NCNP-03 in Boys With DMD (Meteor50) | NS Pharma, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Study of ATX-01 in Participants With DM1 | ARTHEx Biotech S.L. | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | AstraZeneca | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Entrada Therapeutics, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Entrada Therapeutics, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | Dyne Therapeutics | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | Dyne Therapeutics | — | PHASE1/PHASE2 | — | — | — | — | — |
| PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) | Precision BioSciences, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |